BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38556590)

  • 1. Relationships of SIGLEC family-related lncRNAs with clinical prognosis and tumor immune microenvironment in ovarian cancer.
    Jin X; Chen Y; Hu Q
    Sci Rep; 2024 Mar; 14(1):7593. PubMed ID: 38556590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.
    Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L
    Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
    Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
    Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer.
    Feng J; Yu Y; Yin W; Qian S
    J Ovarian Res; 2023 Feb; 16(1):31. PubMed ID: 36739404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Autophagy-Related Genes on the Prognosis and Immune Microenvironment of Ovarian Cancer.
    Zhang J; Yan H; Fu Y
    Biomed Res Int; 2022; 2022():6609195. PubMed ID: 35941978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer.
    Feng S; Yin H; Zhang K; Shan M; Ji X; Luo S; Shen Y
    J Ovarian Res; 2022 Jan; 15(1):10. PubMed ID: 35057848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
    Zhang Z; Wang J; Han W; Zhao L
    BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Lu H; Wu J; Liang L; Wang X; Cai H
    Front Immunol; 2022; 13():803355. PubMed ID: 35154117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
    Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
    Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitophagy-related long non-coding RNA signature predicts prognosis and drug response in Ovarian Cancer.
    Wang J; Zhang X; Zheng F; Yang Q; Bi F
    J Ovarian Res; 2023 Aug; 16(1):177. PubMed ID: 37633972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Hu Y; Chen Y
    Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients.
    Zheng J; Guo J; Zhu L; Zhou Y; Tong J
    J Ovarian Res; 2021 Sep; 14(1):124. PubMed ID: 34560889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    Zhu W; Ye Z; Chen L; Liang H; Cai Q
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer.
    Liu L; Wang Q; Zhou JY; Zhang B
    J Ovarian Res; 2023 Apr; 16(1):88. PubMed ID: 37122030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.